05 May 2026
Beginning May 15, 2026, the Australian Government will cover RSV vaccines for adults aged 75 and over through the National Immunization Program. The government has invested $445.3 million to give eligible Australians free access to the RSV vaccine Arexy, manufactured by GSK, through the National Immunisation Program (NIP). Without listing on the NIP, the RSK vaccination would typically cost $300.
RSV is a common respiratory virus that can lead to hospitalisation, intensive care, and death. Aged care residents are particularly vulnerable due to shared living arrangement and frequent contact with staff and visitors. The addition of the RSV vaccine on the NIP for older adults complements the free NIP influenza and COVID-19 vaccine programs.
Read the Announcement from the Australian Government here
Read the Announcement from GSK here